MCID: DDN027
MIFTS: 43

Duodenum Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Duodenum Disease

MalaCards integrated aliases for Duodenum Disease:

Name: Duodenum Disease 12 15
Duodenal Diseases 56 45
Duodenum Disorder 12
Duodenal Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4072
MeSH 45 D004378
SNOMED-CT 69 52182008
UMLS 74 C0013289

Summaries for Duodenum Disease

MalaCards based summary : Duodenum Disease, also known as duodenal diseases, is related to zollinger-ellison syndrome and multiple endocrine neoplasia, type i. An important gene associated with Duodenum Disease is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and EGFR Transactivation by Gastrin. The drugs Esomeprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, small intestine and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 The duodenum is the first section of the small intestine in most higher vertebrates, including mammals,... more...

Related Diseases for Duodenum Disease

Diseases related to Duodenum Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 zollinger-ellison syndrome 29.6 MEN1 SCT SST
2 multiple endocrine neoplasia, type i 29.6 MEN1 SCT SST
3 chronic cystitis 10.5 CDX2 KRT7
4 rectum adenocarcinoma 10.5 CDX2 KRT7
5 vulva adenocarcinoma 10.5 CDX2 KRT7
6 gastric diffuse adenocarcinoma 10.5 CDX2 KRT7
7 hepatoid adenocarcinoma 10.5 CDX2 MUC1
8 paget disease, extramammary 10.4 KRT7 MUC1
9 spiradenoma 10.4 KRT7 MUC1
10 lymphoepithelioma-like carcinoma 10.4 KRT7 MUC1
11 well-differentiated liposarcoma 10.4 KRT7 MUC1
12 pancreatoblastoma 10.4 MUC1 SST
13 ovary neuroendocrine neoplasm 10.4 CDX2 KRT7
14 alveoli adenoma 10.4 KRAS KRT7
15 ethmoid sinusitis 10.4 MUC1 MUC6
16 appendix adenocarcinoma 10.4 CDX2 KRT7
17 chondroid lipoma 10.4 KRT7 MEN1
18 mucinous adenofibroma 10.4 CDX2 KRT7
19 anus adenocarcinoma 10.4 CDX2 KRT7
20 carcinoid tumors, intestinal 10.4 MEN1 SST
21 mucinous intrahepatic cholangiocarcinoma 10.4 CDX2 MUC6
22 glandular cystitis 10.4 CDX2 KRT7
23 cervical polyp 10.4 CDX2 MUC6
24 insulinomatosis and diabetes mellitus 10.4 SCT SST
25 dumping syndrome 10.4 SCT SST
26 angiodysplasia 10.4 SCT SST
27 vipoma 10.4 SCT SST
28 glucagonoma 10.4 SCT SST
29 endosalpingiosis 10.4 KRT7 MUC1
30 non-functioning pituitary adenoma 10.3 MUC1 SST
31 tumor of exocrine pancreas 10.3 MUC1 MUC6
32 parachordoma 10.3 KRT7 MUC1
33 secretory meningioma 10.3 KRT7 MUC1
34 bile duct mucoepidermoid carcinoma 10.3 KRT7 MUC1
35 pancreatic intraductal papillary-mucinous neoplasm 10.3 MUC1 MUC6
36 middle ear adenoma 10.3 KRT7 MUC1
37 epithelial predominant wilms' tumor 10.3 CDX2 KRT7
38 bowen's disease 10.3 KRT17 KRT7
39 pancreatic somatostatinoma 10.3 MEN1 SST
40 chronic ethmoiditis 10.3 MUC1 MUC6
41 intestinal neuroendocrine benign tumor 10.3 MEN1 SCT
42 microcystic adenoma 10.3 MUC1 MUC6
43 nodular hidradenoma 10.3 KRT7 MUC1
44 hidradenoma 10.3 KRT7 MUC1
45 syringocystadenoma papilliferum 10.3 KRAS MUC1
46 clear cell basal cell carcinoma 10.3 KRT17 KRT7
47 endocervical adenocarcinoma 10.3 CDX2 KRT7 MUC6
48 cystic teratoma 10.3 CDX2 KRT7 MUC6
49 jejunal adenocarcinoma 10.3 CDX2 KRT7
50 mucinous ovarian cystadenoma 10.3 CDX2 KRT7 MUC1

Graphical network of the top 20 diseases related to Duodenum Disease:



Diseases related to Duodenum Disease

Symptoms & Phenotypes for Duodenum Disease

GenomeRNAi Phenotypes related to Duodenum Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.47 HRAS KRAS MUC1
2 Decreased viability GR00106-A-0 9.47 KRAS
3 Decreased viability GR00221-A-1 9.47 HRAS KRAS
4 Decreased viability GR00221-A-2 9.47 HRAS KRAS
5 Decreased viability GR00221-A-3 9.47 HRAS
6 Decreased viability GR00301-A 9.47 KRAS
7 Decreased viability GR00381-A-1 9.47 KRAS
8 Decreased viability GR00402-S-2 9.47 HRAS KRAS MUC1

MGI Mouse Phenotypes related to Duodenum Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 ATP12A ATP4A CDX2 HRAS KRAS KRT17
2 homeostasis/metabolism MP:0005376 9.28 ATP12A ATP4A CCK CDX2 HRAS KRAS

Drugs & Therapeutics for Duodenum Disease

Drugs for Duodenum Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 336)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
2
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 103577-45-3 3883
3
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 138530-94-6, 103577-45-3 9578005
4
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 26787-78-0 33613
5
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81103-11-9 84029
6
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 117976-89-3 5029
7
Trimebutine Approved Phase 4 39133-31-8
8
Metronidazole Approved Phase 4,Phase 2,Phase 3,Not Applicable 443-48-1 4173
9
Calcium polycarbophil Approved Phase 4 126040-58-2
10
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 73590-58-6 4594
11
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
12
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
13
Clopidogrel Approved Phase 4,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
14
Tetracycline Approved, Vet_approved Phase 4,Not Applicable 60-54-8 5353990
15
Ofloxacin Approved Phase 4,Not Applicable 82419-36-1 4583
16
Levofloxacin Approved, Investigational Phase 4,Not Applicable 100986-85-4 149096
17
Erythromycin Approved, Investigational, Vet_approved Phase 4,Not Applicable 114-07-8 12560 441411
18
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
19
Famotidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 76824-35-6 3325
20
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
21
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22204-53-1 156391 1302
22
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3 169590-42-5 2662
23
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
24
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable
25
Azithromycin Approved Phase 4 83905-01-5 55185 447043
26
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
27
Citalopram Approved Phase 4 59729-33-8 2771
28
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
29
Magnesium hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3 1309-42-8
30
Ethanol Approved Phase 4 64-17-5 702
31
Metoclopramide Approved, Investigational Phase 4,Phase 3 364-62-5 4168
32
Dopamine Approved Phase 4,Phase 3,Not Applicable 62-31-7, 51-61-6 681
33
Ranitidine Approved Phase 4,Phase 3,Phase 2,Phase 1 66357-59-3, 66357-35-5 3001055
34
Misoprostol Approved Phase 4,Phase 3 59122-46-2 5282381
35
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
36
Prucalopride Approved Phase 4 179474-81-8
37
Lithium carbonate Approved Phase 4 554-13-2
38
Clozapine Approved Phase 4 5786-21-0 2818
39
Ziprasidone Approved Phase 4 146939-27-7 60854
40
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
41
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
42
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
43
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
44
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
45
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
46
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
47
SB-649868 Experimental, Investigational Phase 4,Phase 1 110-16-7, 110-17-8 444972
48
Furazolidone Experimental, Vet_approved Phase 4,Not Applicable 67-45-8 5323714 3435
49 Mosapride Investigational Phase 4,Not Applicable 112885-41-3
50 Rebamipide Investigational Phase 4,Phase 2,Phase 3,Not Applicable 90098-04-7

Interventional clinical trials:

(show top 50) (show all 710)
# Name Status NCT ID Phase Drugs
1 Oral vs Intravenous and Proton Pump Inhibitor (PPI)for Peptic Ulcer Bleeding (PUB) Unknown status NCT01123031 Phase 4 lansoprazole;esomeprazole
2 Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer Unknown status NCT00471029 Phase 4 esomeprazole
3 Helicobacter Pylori Empiric Treatment in Ulcer Bleeding Unknown status NCT00687336 Phase 4
4 H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection Unknown status NCT00926809 Phase 4 Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin;Lansoprazole (proton pump inhibitor), placebo
5 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
6 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
7 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
8 Concomitant Therapy of H. Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
9 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Unknown status NCT01882088 Phase 4 Mucofalk
10 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
11 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
12 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
13 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
14 The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients Completed NCT02648659 Phase 4 Ilaprazole;Amoxicillin;Clarithromycin;Metronidazole
15 Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot Completed NCT02536989 Phase 4 omeprazole;omeprazole
16 Fast-track Surgery for Perforated Peptic Ulcers Completed NCT01620671 Phase 4
17 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers Completed NCT01353144 Phase 4 aspirin
18 Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion Completed NCT00843063 Phase 4 pantoprazole vs famotidine
19 The Dissemination of Consensus Recommendations on Upper Gastrointestinal Bleeding Completed NCT00840008 Phase 4
20 Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers Completed NCT00778193 Phase 4 Naproxen;Aspirin;Celecoxib;Clopidogrel;Placebo
21 Ulcer Prevention Study in Post Gastric Bypass Patients Completed NCT00557349 Phase 4 Omeprazole;Famotidine
22 Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment Completed NCT00534443 Phase 4
23 Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population Completed NCT00137033 Phase 4 Celecoxib;Naproxen;ASA
24 Argon Plasma Coagulation for Bleeding Peptic Ulcers Completed NCT02241044 Phase 4
25 The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia Completed NCT01822600 Phase 4 Human albumin;Omeprazole
26 The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers Completed NCT01591083 Phase 4 esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
27 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
28 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
29 Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy Completed NCT00164866 Phase 4 Omeprazole
30 Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
31 Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding Completed NCT00731601 Phase 4 pantoprazole;pantoprazole
32 Empirical Rescue Therapies of Helicobacter Pylori Infection Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
33 Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
34 Aizthromycin or Clarithromycin in H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
35 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate
36 Clarithromycin Resistant Tailored Therapy Completed NCT01453036 Phase 4
37 Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers Completed NCT00279123 Phase 4 pantoprazole infusion;pantoprazole bolus;no treatment
38 Effect of Citalopram on Reflux Episodes in Healthy Volunteers Completed NCT03746691 Phase 4 Citalopram HCl;Placebos
39 Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
40 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
41 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
42 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
43 Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy Completed NCT00272467 Phase 4 Rebamipide;Omeprazole
44 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
45 Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer Completed NCT00239551 Phase 4 Prevacid
46 Post-Marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer Completed NCT00233389 Phase 4 Rebamipide
47 A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium Completed NCT00125736 Phase 4 E0671;rabeprazole sodium;E0671 placebo
48 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
49 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
50 An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium Completed NCT00428701 Phase 4 Esomeprazole Sodium

Search NIH Clinical Center for Duodenum Disease

Cochrane evidence based reviews: duodenal diseases

Genetic Tests for Duodenum Disease

Anatomical Context for Duodenum Disease

MalaCards organs/tissues related to Duodenum Disease:

42
Testes, Small Intestine, Lung, Liver, Colon, Heart, Pancreas

Publications for Duodenum Disease

Articles related to Duodenum Disease:

# Title Authors Year
1
Imaging of non-neoplastic duodenal diseases. A pictorial review with emphasis on MDCT. ( 29388052 )
2018
2
Imaging spectrum of nonneoplastic duodenal diseases. ( 27572283 )
2016
3
To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. ( 25780285 )
2015
4
Helicobacter pylori genetic diversity and gastro-duodenal diseases in Malaysia. ( 25503415 )
2014
5
Association of genetic polymorphisms in IL17A and IL17F with gastro-duodenal diseases. ( 23012664 )
2012
6
Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. ( 17934843 )
2008
7
A simple multiplex PCR assay for diagnosing virulent Helicobacter pylori infection in human gastric biopsy specimens from subjects with gastric carcinoma and other gastro-duodenal diseases. ( 17850305 )
2007
8
The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. ( 18039108 )
2006
9
Correlation between erosive oesophageal and gastro-duodenal diseases. the influence of aspirin, simple analgesics, and Helicobacter pylori. ( 12468951 )
2002
10
ABO blood groups and gastro-duodenal diseases. ( 13355800 )
1956

Variations for Duodenum Disease

Expression for Duodenum Disease

Search GEO for disease gene expression data for Duodenum Disease.

Pathways for Duodenum Disease

GO Terms for Duodenum Disease

Biological processes related to Duodenum Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of long-term neuronal synaptic plasticity GO:0048169 9.4 HRAS KRAS
2 cellular sodium ion homeostasis GO:0006883 9.37 ATP12A ATP4A
3 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.32 ATP12A ATP4A
4 cellular potassium ion homeostasis GO:0030007 9.26 ATP12A ATP4A
5 sodium ion export across plasma membrane GO:0036376 9.16 ATP12A ATP4A
6 response to isolation stress GO:0035900 8.96 HRAS KRAS
7 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.92 HRAS KRAS MUC1 MUC6

Molecular functions related to Duodenum Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.33 CCK SCT SST
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
3 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Duodenum Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....